Saruplase versus other fibrinolytic agents.
Michels
H R
HR
Catharina Ziekenhuis, Afdeling Cardiologie, Eindhoven, The Netherlands.
D005340:Fibrinogen / Q000187:drug effects; D005343:Fibrinolytic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D013300:Streptokinase / Q000494:pharmacology / Q000627:therapeutic use; D015912:Thrombolytic Therapy / Q000379:methods; D014568:Urokinase-Type Plasminogen Activator / Q000494:pharmacology / Q000627:therapeutic use*
D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D005340:Fibrinogen; D013300:Streptokinase; D014568:Urokinase-Type Plasminogen Activator; C067551:saruplase